Health Ministry is of the view that a potential compulsory license applicant must attempt to procure voluntary license from the patent holder which was not the case with Cipla. Novartis’ patent on the drug was not revoked. There was no case for Compulsory Licensing under S.92.
Novartis has filed a case against Cipla contending for infringing patents covering Onbrez. The drug is protected by 5 patents in India. In putting forth their cause, the Pharmaceutical giant contends that there is ample supply of Onbrez.
Novartis has also made a claim for Trade Mark Infringement. Cipla’s generic version (Unibrez) is deceptively similar to Novartis’ Onbrez which may cause confusion among the people. The Delhi High Court granted permanent injunction in Novartis’ favour. Cipla hopes to find a way out of this battle, by proposing to use the mark “Indaflo”, but of course nothing can be changed till the suit is on.